US20020188185A1 - Percutaneous biological fluid sampling and analyte measurement devices and methods - Google Patents
Percutaneous biological fluid sampling and analyte measurement devices and methods Download PDFInfo
- Publication number
- US20020188185A1 US20020188185A1 US09/879,106 US87910601A US2002188185A1 US 20020188185 A1 US20020188185 A1 US 20020188185A1 US 87910601 A US87910601 A US 87910601A US 2002188185 A1 US2002188185 A1 US 2002188185A1
- Authority
- US
- United States
- Prior art keywords
- micro
- biological fluid
- needle
- electrode
- sampling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150977—Arrays of piercing elements for simultaneous piercing
- A61B5/150984—Microneedles or microblades
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15186—Devices loaded with a single lancet, i.e. a single lancet with or without a casing is loaded into a reusable drive device and then discarded after use; drive devices reloadable for multiple use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
Definitions
- This field of this invention is minimally invasive biological fluid sampling and analyte measurement devices.
- Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in the diagnosis and management of a variety of disease conditions.
- Common analytes of interest include glucose, e.g., for diabetes management, cholesterol, and the like.
- a common technique for collecting a sample of blood for analyte determination is to pierce the skin at least into the subcutaneous layer to access the underlining blood vessels in order to produce localized bleeding on the body surface.
- the accessed blood is then collected into a small tube for delivery and analyzed by testing equipment, often in the form of a hand-held instrument having a reagent test strip onto which the blood sample is placed.
- the fingertip is the most frequently used site for this method of blood collection due to the large number of small blood vessels located therein. This method has the significant disadvantage of being very painful because subcutaneous tissue of the fingertip has a large concentration of nerve endings. It is not uncommon for patients who require frequent monitoring of an analyte to avoid having their blood sampled.
- micro-needles or analogous structures to access the interstitial fluid within the skin.
- the micro-needles are penetrated into the skin to a depth less than the subcutaneous layer so as to minimize the pain felt by the patient.
- the interstitial fluid is then sampled and tested to determine the concentration of the target constituent.
- the concentration of a constituent within the interstitial fluid is representative of the concentration of that constituent in other bodily fluids, such as blood.
- the corresponding level of glucose in the patient's blood can be derived.
- U.S. Pat. Nos. of interest include: 5,161,532, 5,582,184, 5,746,217, 5,820,570, 5,879,310, 5,879,367, 5,942,102, 6,080,116, 6,083,196, 6,091,975 and 6,162,611.
- Other patent documents and publications of interest include: WO 97/00441, WO 97/42888, WO 98/00193 WO 98/34541, WO 99/13336, WO 99/27852, WO 99/64580, WO 00/35530, WO 00/45708, WO 00/57177, WO 00/74763 and WO 00/74765A 1 .
- the subject device includes an elongated sampling means configured to pierce a skin surface to provide access to biological fluid, and concentrically-spaced working and reference electrodes positioned within the elongated sampling means that define an electrochemical cell for measuring the concentration of analyte within the biological fluid.
- the device further includes an insulating material positioned between the concentrically-spaced electrodes.
- the device also includes means for making an electrochemical measurement of an analyte in the electrochemical cell, e.g., a coulometric, amperometric or potentiometric measurement.
- the subject device is characterized by a piercing member made of coaxially spaced-apart working and reference electrodes that provide for an electrochemical reaction cell, whereby a reaction area or zone is between the electrodes.
- the electrochemical cell is employed to make an electrochemical measurement of an analyte in a sample of biological fluid that has been accessed by the piercing member and transported into the electrochemical cell.
- a porous material is positioned in the space between the electrodes to define the reaction area or zone, that acts to optimally position the electrodes with respect to each other, usually in a parallel configuration.
- the porous material comprises a plurality of pores that exert a capillary action on the sampled fluid, causing the fluid to be drawn into the porous material.
- An exemplary method of the subject invention involves using at least one subject micro-needle having an open distal end and an electrochemical cell therein.
- the electrochemical cell may further include a redox reagent system and a concentrically-layered electrode configuration, e.g., coaxially working and reference electrodes.
- the micro-needle is inserted into the skin to a selected depth, preferably to a depth that avoids contacting nerve endings and blood vessels.
- the sample of biological fluid present at the open distal end of the micro-needle is then wicked, by means of a capillary force, into the electrochemical cell.
- An electrochemical measurement is then made between the working and reference electrodes, where such a measurement provides an electrical signal that is representative of the concentration the constituent in the sample.
- concentration of the constituent in the patient's blood is then derived from the obtained electrical signal.
- a numerical value representing this concentration may then be displayed on a display unit.
- a software algorithm that is part of the device, e.g., programmed into the control unit present in the device, may be employed to determine the signal levels transmitted by the control unit to the cell and for deriving the concentration level of the target analyte.
- the subject invention includes a system characterized by one or more devices, each in the form of a micro-piercing member, a control unit, a display unit and a housing. Also provided by the subject inventions are kits for use in practicing the methods of the subject invention.
- the subject devices, systems, methods and kits find use in analyte concentration measurement of a variety of analytes and are particularly suited for use in the measurement of glucose concentration in interstitial fluid.
- FIG. 1 includes FIGS. 1A, 1B, 1 C and 1 D wherein FIG. 1A is a partial cut-away view of a length of a micro-needle of the present invention, FIG. 1B is a cross-sectional view of the micro-needle of FIG. 1A along the arrows b-b, FIG. 1C is a cross-sectional view of the micro-needle of FIG. 1A along the arrows c-c and FIG. 1D is a top view of the micro-needle of FIG. 1A along the arrows d-d; and
- FIG. 2 is a schematic representation of the sampling and measurement device of the present invention.
- Percutaneous devices and systems, as well as methods for using the same are provided by the subject invention.
- a feature of the subject devices is the presence of a piercing member that includes concentric working and reference electrodes that define an electrochemical cell having a reaction area or zone into which accessed fluid flows and with which an electrochemical measurement of an analyte present in accessed fluid present therein is made.
- the present invention finds use in the sampling of biological fluids such as blood, blood fractions, interstitial fluid and the like, and in the detection and measurement of a variety of different analytes, e.g., glucose, cholesterol, electrolytes, pharmaceuticals, illicit drugs, and the like.
- analytes e.g., glucose, cholesterol, electrolytes, pharmaceuticals, illicit drugs, and the like.
- test strip includes a plurality of such test strips
- processor includes reference to one or more processors and equivalents thereof known to those skilled in the art, and so forth.
- the devices of the subject invention generally include a skin-penetration means, a fluid sampling means and a constituent measurement means, in many embodiments integrated into a single structure.
- the skin-penetration means has at least one micro-piercing member, e.g., a micro-needle or the like, used to penetrate the skin to a depth where pain and bleeding are minimized, and preferably non-existent.
- the micro-needle penetrates above the level where nerves are present.
- target skin layers into which the subject piercing members may extend to include the dermis, epidermis and the stratum corneum (i.e. the outermost layer of the epidermis).
- the devices further include a fluid sampling means, where such fluid sampling means is provided by the construct and geometry of the micro-needle itself, and more particularly, its internal construct and geometry.
- the micro-needle has a generally elongated shape and an open distal tip extending into a space or spaces within its structure that are small enough to create a capillary force on fluid present at the open distal tip.
- the capillary force acts to access or draw the fluid (e.g., interstitial fluid and/or blood if so desired and depending on the length of the micro-needle) into a space within the micro-needle and then positions the sampled fluid to be measured by a measurement means.
- the constituent measurement means of the subject invention is made up of an electrochemical cell formed within the structure of the microneedle to measure the concentration of a constituent, e.g., an analyte, within the fluid sample.
- the electrochemical cell includes an electrode arrangement of a working electrode and a reference electrode that provides an input reference signal to the sampled fluid and an output signal representing the concentration of the target constituent or analyte in the sampled fluid.
- Various electrochemical systems may be employed by the present invention, including systems that are amperometric (i.e., measures current), coulometric (i.e., measures electrical charge) or potentiometric (i.e., measures voltage).
- the biological fluid sampling and analyte concentration measurements devices each comprise at least two electrodes, a reference electrode and a working electrode.
- the reference electrode provides the input signal to the electrochemical cell and the working electrode provides the output measurement signal from the cell.
- the electrodes are separated by a porous insulator that defines a reaction zone within the micro-needle, where such a porous insulator acts to optimally position the electrodes with respect to each other.
- the porous insulator acts as a component of the sampling means by providing a capillary-type wicking action or the like sufficient to move or draw sampled fluid into the electrochemical cell.
- the subject micro-needle includes a redox reagent system, typically on the reactive surface of one or both electrodes.
- the redox reagent system may be contained within the porous insulator.
- the redox reagent system typically comprises one or more enzymes and a mediator.
- the electrochemical cell is in electrical communication with a control means that sets the input reference signal transmitted to the electrochemical cell, receives an output signal from the electrochemical cell and then derives the concentration level of the constituent within the sample from the output signal.
- the working and references electrodes are in electrical communication with a means for making an electrochemical measurement using the working and reference electrodes, e.g., a means for applying an electrical current between the two electrodes, measuring a change in the current over time and relating the observed change in current to the concentration of analyte present in the electrochemical cell.
- the detection and/or concentration of a constituent or analyte in a patient's or user's biological fluid is then derived from the concentration level in the fluid sample, the numerical value of which may then be displayed to the patient or user on a display unit.
- control and display units are integrally housed within a low-profile housing.
- the housing may take a form that also provides a means of securing or holding one or more micro-needles in a position and arrangement suitable for the particular sampling and measuring application at hand.
- the geometry and construct of the subject device provides three functions in a single micro-needle structure: penetration into the skin, collection of a sample of biological fluid and measurement of a constituent or analyte in that sample.
- the collection and measurement steps are performed completely in-situ, obviating the conventional techniques of withdrawing a sample from the skin, placing the sample on a reagent test strip, or the like, and using a separate piece of equipment or means to test the sample.
- in-situ detection minimizes the lag time associated with obtaining measurement readings of a sample compared to previous diagnostic methods that rely on first extracting biological fluid before the measurement can take place.
- a feature of the subject invention is a skin-penetration means having at least one micro-piercing member, e.g., a micro-needle or the like.
- an aspect of the present invention is that it eliminates or at least greatly minimizes the pain and bleeding suffered by a patient during the sampling process. Accordingly, the penetration lengths and diameters of the micro-needles must be within certain ranges to accomplish this goal. Of course, those values will vary depending on the type of biological fluid (e.g., interstitial fluid, blood or both) desired for sampling, the skin layer to be accessed and the thickness of the skin layers of the particular patient or device user being tested.
- the skin includes three distinct layers, a top layer called the epidermis, a middle layer called the dermis and a bottom layer called the subcutaneous layer.
- the epidermis is about 60 to 120 ⁇ m (microns) thick and comprises four distinct layers: a 10 to 20 ⁇ m outer layer, called the stratum corneum, followed by the stratum granulosum, stratum malpighii and stratum germinativum.
- the stratum corneum contains cells filled with bundles of cross-linked keratin and keratohyalin surrounded by an extracellular matrix of lipids.
- the inner three layers are collectively referred to as the viable epidermis and have a total thickness in the range of about 50 to 100 ⁇ m.
- the viable epidermis is responsible for diffusing metabolites to and from the dermis.
- the epidermis contains no blood cells or nerve endings.
- the dermis is much thicker than the epidermis, having a thickness in the range from about 2,000 to 3,000 ⁇ m.
- the dermal layer generally consists of a dense bed of connective tissue, including collagen fibers, and interstitial fluid dispersed throughout these fibers. Below the dermal layer is the subcutaneous tissue that contains the blood capillaries and the majority of nerve endings within the skin.
- the micro-needles of the present invention may have lengths that extend no deeper than stratum comeum, the epidermis or the dermis layer when fully penetrated into the skin to minimize the pain felt by the patient; however, they may be longer if necessary for the particular sampling application at hand.
- the length-to-diameter aspect ratio of the micro-needle is important in determining an optimal length for the subject micro-needles. Accordingly, in order to effectively and atraumatically penetrate the skin, the length of the micro-needle is usually at least about 5 times greater than the diameter of the micro-needle, but may be more or less.
- the minimum micro-needle diameter is dependent upon the necessary spacing between the electrodes and the diameters of the other components of the electrochemical cell.
- the subject micro-needles generally have a length in the range from about 500 to 4,000 ⁇ m, typically between about 600 to 3,000 ⁇ m, and more typically between about 1,000 to 2,000 ⁇ m; however, these lengths will vary from patient to patient depending on the various factors as noted above, and on the thickness of the skin layers of the particular patient being tested.
- the micro-needles of the subject invention may have lengths that are longer than the depth of the target skin layer, the micro-needle may be penetrated into the skin at a depth (referred to as the penetration length) that is less than the length of the micro-needle structure.
- the micro-needles in many embodiments have a penetration length in the range from about 50 to 4,000 ⁇ m, and more typically from about 100 to 3,000 ⁇ m.
- the penetration length of the micro-needle is typically between about 50 to 120 ⁇ m.
- the penetration length of the micro-needle is typically from about 2,000 to 3,000 ⁇ m.
- Micro-needle 100 has a configuration that is substantially straight along the longitudinal axis and has a substantially circular cross-section.
- any suitable cross-sectional configuration may be employed including, but not limited to, other annular shapes such as elliptical and oblong, or polygonal configurations, such as square and rectangular.
- the outer diameter of a micro-needle at its thickest point typically does not exceed about 350 ⁇ m and is usually between about 200 ⁇ m to 300 ⁇ m. In certain embodiments the outer diameter is typically about 250 ⁇ m.
- Micro-needle 100 terminates at distal end 104 , in preferably a sharp tip 102 having a beveled or sliced configuration, as shown in FIG. 1D, to more easily penetrate the skin.
- tip 102 may have other suitable configurations such as one that is not tapered and defines an edge that lies in a plane perpendicular to the longitudinal axis of the micro-needle (not shown).
- micro-needles in the form of an array, may be employed by the present invention.
- the number of micro-needles employed will depend upon various factors including the agent being detected, the body surface location into which the micro-needles are inserted, the sample site, the fluid volume and the like.
- the micro-needle array may include micro-needles having varying shapes, lengths, widths and tip configurations.
- Micro-needle 100 includes an electrochemical cell that provides an electrical signal or signals representative of the concentration of the analyte being measured in a sampled biological fluid.
- the electrochemical cell comprises various components or layers arranged concentrically with respect to each other. In many embodiments, this concentric arrangement may also be circumferential or co-axial.
- micro-needle 100 includes, a solid wire core 106 and an outer plating 114 .
- the solid wire core 106 provides rigidity to the micro-needle structure and may be part of the adjacent electrode.
- the outer plating 114 may be made of stainless steel or the like. Between wire core 106 and outer plating 114 resides the subject electrochemical cell, which includes, from inside out, a first or inner electrode 108 , a porous insulator 110 and a second or outer electrode 112 .
- second or outer electrode 112 and outer plating 114 extend to define edge 116 and tip 102 of micro-needle 100 .
- the three innermost layers, insulator 110 , first electrode 108 and solid wire core 106 extend evenly to a location or area 118 (proximal to distal end 104 ), wherein these three layers have distal edges that are substantially flush with each other.
- Lumen 120 acts to create a capillary force which wicks biological fluid present into lumen opening 128 at tip 102 .
- Lumen 120 has a volume which does not exceed about 250 nL and is generally in the range from about 20 to 140 nL. In certain embodiments the volume is typically about 65 nL.
- Porous insulator 110 then provides a secondary capillary force to wick an amount of the biological fluid contained within lumen 120 into itself.
- Solid wire core 106 has a diameter which typically does not exceed about 120 ⁇ m, and more typically is in the general range from about 80 to 100 ⁇ m. In certain embodiments the diameter is typically about 90 ⁇ m.
- First electrode 108 has a cylindrical configuration (although other configurations are possible) having a thickness which typically does not exceed about 300 ⁇ , and more typically is in the general range from about 70 to 200 ⁇ . In certain embodiments the thickness is typically about 100 ⁇ .
- Porous insulator 110 also has a cylindrical configuration (although other configurations are possible) having a thickness which typically does not exceed about 200 ⁇ m, and more typically is in the general range from about 50 to 80 ⁇ m.
- Second electrode 112 also has a cylindrical configuration (although other configurations are possible) having a thickness which typically does not exceed about 300 ⁇ and more typically is in the general range from about 70 to 200 ⁇ .
- the thin outer tube 114 upon which the second electrode 112 is electroplated has a thickness which typically does not exceed about 25 ⁇ m and more typically is in the general range from about 12 to 20 ⁇ m.
- the electrode 112 i.e., the outer electrode
- the reference electrode i.e., the electrode which provides an input signal to the electrochemical cell
- the other electrode 108 i.e., the inner electrode
- the working electrode i.e., the electrode which provides an output signal representative of the analyte concentration within the sampled fluid.
- the length of the outer electrode is the same as the length of the micro-needle, and thus is generally not greater than about 4,000 ⁇ m. More typically, the length of the outer electrode is between about 1,000 ⁇ m to 3,000 ⁇ m, and usually is about 2,000 ⁇ m.
- the inner electrode may have the same length as the outer electrode, but may often times be shorter than the outer electrode.
- the length of the inner electrode is generally about 20% shorter than the outer electrode and is generally not greater than about 3,200 ⁇ m, and is typically between about 800 to 2,400 ⁇ m, and is more typically about 1,600 ⁇ m.
- At least the surfaces of the electrodes that face the reaction zone (i.e., the porous insulator) within the micro-needle are made of highly conductive metal, such as palladium, gold, platinum, silver, iridium, carbon, doped indium tin oxide, stainless steel and the like, or a combination of such materials. Most typically the metal is gold, platinum or palladium.
- each electrode may be made up of an inert support or backing substrate, on the surface of which is a thin layer of the metal component (e.g., an electroplated metal layer) of the electrode.
- the working and reference electrodes define the boundaries of the reaction zone that, in the embodiment of FIG. 1, is in the form of a cylindrical donut, for example.
- the reaction zone is filled with a hydrophilic porous insulator having an inner and an outer surface area and having a thickness that typically does not exceed 150 ⁇ m and generally is in the range from about 50 to 80 ⁇ m.
- the volume of the reaction zone typically does not exceed about 150 nL and is generally from about 15 to 110 nL. In certain embodiments the volume is typically about 50 nL.
- the porous insulator comprises pores or voids throughout at least a portion of the micro-needle structure.
- the pores are sufficiently sized to provide a capillary force so as to wick in fluid from lumen 120 .
- the pores are also sufficiently interconnected to permit passage of or conduction of a fluid through the porous material.
- the average pore size is from about 1000 to 5000 nm and more typically about 1000 to 2000 nm.
- the porous insulator may be made of ceramics or plastic materials such as polymers. Suitable types of polymer materials include, but are not limited to, polyimides, polysulfone, and cellulosic. As is well known in the art, polymers may be rendered porous by removing leachable or volatizable material contained therein.
- a redox reagent(s) system is typically employed to single out and sense the target analyte or constituent selected to be analyzed over the other constituents in the sampled biological fluid.
- the redox reagent(s) of the redox reagent system may reside on the reactive surface, i.e., the surface facing the porous insulator, of one or both electrodes, but in many embodiments the redox reagent(s) will reside on the reactive surface of the working electrode.
- the reagent is often times coated or deposited on the surface(s) by means of dip coating, where such processes are well known in the art.
- the reagent may be contained within the porous insulator by saturation coating, as is known in the art.
- the reagent system used is selected based on the analyte targeted for detection. The interaction of the reagent system and the corresponding constituent or analyte determines the concentration of the target analyte or constituent in the cell.
- the reagent system present in the reaction area typically includes at least an enzyme(s) and a mediator.
- the enzyme member(s) of the reagent system is an enzyme or a plurality of enzymes that work in concert to oxidize the analyte of interest.
- the enzyme component of the reagent system is made up of a single analyte oxidizing enzyme or a collection of two or more enzymes that work in concert to oxidize the analyte of interest.
- Enzymes of interest include oxidases, dehydrogenases, lipases, kinases, diaphorases, quinoproteins and the like.
- the specific enzyme present in the reaction area depends on the particular analyte for which the electrochemical test strip is designed to detect, where representative enzymes include: glucose oxidase, glucose dehydrogenase, cholesterol esterase, cholesterol oxidase, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate oxidase, lactate oxidase, lactate dehydrogenase, pyruvate oxidase, alcohol oxidase, bilirubin oxidase, uricase, and the like.
- the enzyme component of the reagent system is a glucose-oxidizing enzyme (e.g., a glucose oxidase or glucose dehydrogenase).
- the reagent system may further include a second component, i.e., a mediator component, which is made up of one or more mediator agents.
- mediator agents include: ferricyanide, phenazine ethosulphate, phenazine methosulfate, pheylenediamine, 1-methoxy-phenazine methosulfate, 2,6-dimethyl-1,4-benzoquinone, 2,5-dichloro-1,4-benzoquinone, ferrocene derivatives, osmium bipyridyl complexes, ruthenium complexes and the like.
- mediator of particular interest is ferricyanide.
- buffering agents e.g., citraconate, citrate, phosphate
- Good buffers e.g., “Good” buffers and the like.
- the reagent(s) is generally present in dry form.
- the amounts of the various components may vary, wherein the amount of enzyme component typically ranges from about 0.1 to 10% by weight.
- the subject invention includes a system for sampling biological fluid from the skin of a patient or user and measuring a target constituent within the biological fluid, where such a system generally is made of at least one micro-needle having a sampling means, a reagent and an electrochemical cell, as described above, and a control unit having means for sending and receiving electrical signals and a software algorithm.
- System 50 includes a hand-held control unit 52 and a device 10 , as described above, operatively mounted to distal end 54 of control unit 52 .
- Device 10 includes an array of the micro-needles of the present invention, such as micro-needle 100 of FIG. 1.
- Control unit 52 has a housing 56 , typically made of a medical grade plastic material, having a low-profile configuration which houses a means (not shown) for controlling the measurement means of device 10 , i.e., generating and transmitting input reference signals to the electrochemical cell of micro-needle 100 and receiving output measurement signals from the cell.
- Housing 56 may further include a means for supporting the micro-needle array or a single micro-needle, such as a support or substrate or the like (not shown).
- a software algorithm programmed within control unit 52 automatically calculates and determines the concentration of the target analyte in the biological sample upon receipt of the output signal.
- the concentration level (among other desired information) is then transmitted to an external display means or screen 58 that displays information to the user.
- Control interface buttons 60 are provided to allow the user to input information to the control means, such as the type of analyte targeted for measurement.
- Device 10 is electrically and physically coupled to control unit 52 . Electrical communication between the two is established by means of conductive contacts (not shown) on device 10 and corresponding electrical traces (not shown) within control unit 52 .
- device 10 and control unit 52 are physically coupled by a quick lock-and-release mechanism (many of which are commonly known) such that a used device can be easily removed and replaced.
- Control unit 52 is typically reusable and usable with any number of devices of the subject invention.
- Also provided by the subject invention are methods for using the subject devices and systems to determine the concentration of an analyte in a biological sample.
- a variety of different analytes may be detected using the subject devices and systems, where representative analytes include, but are not limited to, glucose, cholesterol, lactate, alcohol, electrolytes, pharmaceuticals, illicit drugs, and the like.
- the first step is to provide a device 10 having one or more micro-needles 100 of the present invention.
- device 10 is particularly configured (i.e., device 10 includes the appropriate reagent(s)) for targeting the analyte(s) of interest.
- the device 10 is operatively engaged and interfaced with a control unit 52 that can be manually held and controlled by the user.
- Control unit 52 is programmed for testing the targeted analyte(s).
- the device 10 is positioned over a selected area of the user's skin, and, with slight pressure, the array of micro-needles 100 of device 10 are caused to penetrate into the skin.
- the depth to which the micro-needles 12 are inserted will depend on the length of the respective micro-needles or by some other means associated with the device 10 for limiting the insertion depth.
- an amount (i.e., a sample) of biological fluid present at the open tips 102 of micro-needles 100 is caused to wick into lumens 120 of the respective micro-needles by means of a capillary force, i.e., most or all of the biological fluid is transferred in situ into the device 10 .
- the porous insulator 110 continues to wick the fluid into the reaction zone of the electrochemical cell by means of a capillary force.
- micro-needle 100 may be manufactured with a selected redox reagent system placed on opposing surfaces 124 and 126 of first electrode 108 and second electrode 112 , respectively, or alternatively, the reagent is infused within porous insulator 110 .
- the type of reagent system is selected based on the type of analyte targeted for measurement.
- the targeted analyte within the sample chemically reacts with the reagent, causing the analyte to oxidize. This chemical reaction creates a change in the impedance (or resistance) level across the reaction zone within the electrochemical cell.
- the targeted analyte chemically reacts with the selected reagent(s) to form electroactive products.
- the electroactive products are then either oxidized or reduced by the optional mediator or directly by the working electrode 108 .
- the resulting output signal level is then conducted to the control unit by electrode 108 .
- a software algorithm programmed within control unit 52 then automatically determines the differential between the output and reference signals, derives the concentration of analyte in the sample from this differential value, and then derives the corresponding concentration level of the selected analyte in the patient's blood. Any or all of these values may be displayed by display means or screen 58 .
- a device such as control unit 52 which automatically calculates and determines the concentration of a selected analyte in a biological sample and/or in the patient's system, such that a user need only insert a micro-needle of the subject invention into the patient's skin and then read the final analyte concentration result from a display of the device, is further described in U.S. Pat. No. 6,193,873 entitled “Sample Detection to Initiate Timing of an Electrochemical Assay,” the disclosure of which is herein incorporated by reference.
- kits for use in practicing the subject methods include at least one subject device having one or more micro-needles.
- the kits may also include a reusable or disposable control unit that may be used with reusable or disposable devices of the kit or from other kits of the subject invention.
- These kits may include devices having an array of micro-needles having the same or different lengths.
- Certain kits may include various devices each containing the same or different reagents.
- kits include instructions for using the subject devices in the determination of an analyte concentration in a physiological sample. These instructions may be present on one or more of the packaging, a label insert, or containers present in the kits, and the like.
- the subject inventions are easy to use and can provide for analyte testing without the need to cut or lance the skin and with minimal or no pain and blood. As such, the subject invention represents a significant contribution to the field.
Abstract
Description
- This field of this invention is minimally invasive biological fluid sampling and analyte measurement devices.
- The detection of analytes in biological fluids is of ever increasing importance. Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in the diagnosis and management of a variety of disease conditions. Common analytes of interest include glucose, e.g., for diabetes management, cholesterol, and the like.
- A common technique for collecting a sample of blood for analyte determination is to pierce the skin at least into the subcutaneous layer to access the underlining blood vessels in order to produce localized bleeding on the body surface. The accessed blood is then collected into a small tube for delivery and analyzed by testing equipment, often in the form of a hand-held instrument having a reagent test strip onto which the blood sample is placed. The fingertip is the most frequently used site for this method of blood collection due to the large number of small blood vessels located therein. This method has the significant disadvantage of being very painful because subcutaneous tissue of the fingertip has a large concentration of nerve endings. It is not uncommon for patients who require frequent monitoring of an analyte to avoid having their blood sampled. With diabetics, for example, the failure to frequently measure their glucose level on a prescribed basis results in a lack of information necessary to properly control the level of glucose. Uncontrolled glucose levels can be very dangerous and even life-threatening. This technique of blood sampling also runs the risk of infection and the transmission of disease to the patient, particularly when done on a high-frequency basis. The problems with this technique are exacerbated by the fact that there is a limited amount of skin surface that can be used for the frequent sampling of blood.
- To overcome the disadvantages of the above technique and others that are associated with a high degree of pain, certain analyte detection protocols and devices have been developed that use micro-needles or analogous structures to access the interstitial fluid within the skin. The micro-needles are penetrated into the skin to a depth less than the subcutaneous layer so as to minimize the pain felt by the patient. The interstitial fluid is then sampled and tested to determine the concentration of the target constituent. The concentration of a constituent within the interstitial fluid is representative of the concentration of that constituent in other bodily fluids, such as blood. Thus, by sampling interstitial fluid and measuring the level of glucose therein, for example, the corresponding level of glucose in the patient's blood can be derived.
- Despite the work that has already been done in the area of analyte testing, there is a continued interest in the identification of new analyte detection methods that more readily meet the needs of the relevant market. Of particular interest would be the development of a minimally invasive analyte detection system that is practical, manufacturable, accurate, easy to use, as well as safe and efficacious.
- U.S. Pat. Nos. of interest include: 5,161,532, 5,582,184, 5,746,217, 5,820,570, 5,879,310, 5,879,367, 5,942,102, 6,080,116, 6,083,196, 6,091,975 and 6,162,611. Other patent documents and publications of interest include: WO 97/00441, WO 97/42888, WO 98/00193 WO 98/34541, WO 99/13336, WO 99/27852, WO 99/64580, WO 00/35530, WO 00/45708, WO 00/57177, WO 00/74763 and WO 00/74765A1.
- Minimally invasive biological fluid sampling and analyte measurement devices and systems, as well as methods for using the same, are provided. Generally, the subject device includes an elongated sampling means configured to pierce a skin surface to provide access to biological fluid, and concentrically-spaced working and reference electrodes positioned within the elongated sampling means that define an electrochemical cell for measuring the concentration of analyte within the biological fluid. In certain embodiments, the device further includes an insulating material positioned between the concentrically-spaced electrodes. The device also includes means for making an electrochemical measurement of an analyte in the electrochemical cell, e.g., a coulometric, amperometric or potentiometric measurement.
- In a more specific embodiment, the subject device is characterized by a piercing member made of coaxially spaced-apart working and reference electrodes that provide for an electrochemical reaction cell, whereby a reaction area or zone is between the electrodes. The electrochemical cell is employed to make an electrochemical measurement of an analyte in a sample of biological fluid that has been accessed by the piercing member and transported into the electrochemical cell. A porous material is positioned in the space between the electrodes to define the reaction area or zone, that acts to optimally position the electrodes with respect to each other, usually in a parallel configuration. The porous material comprises a plurality of pores that exert a capillary action on the sampled fluid, causing the fluid to be drawn into the porous material.
- An exemplary method of the subject invention involves using at least one subject micro-needle having an open distal end and an electrochemical cell therein. The electrochemical cell may further include a redox reagent system and a concentrically-layered electrode configuration, e.g., coaxially working and reference electrodes. The micro-needle is inserted into the skin to a selected depth, preferably to a depth that avoids contacting nerve endings and blood vessels. Next, the sample of biological fluid present at the open distal end of the micro-needle is then wicked, by means of a capillary force, into the electrochemical cell. An electrochemical measurement is then made between the working and reference electrodes, where such a measurement provides an electrical signal that is representative of the concentration the constituent in the sample. The concentration of the constituent in the patient's blood is then derived from the obtained electrical signal. A numerical value representing this concentration may then be displayed on a display unit. A software algorithm that is part of the device, e.g., programmed into the control unit present in the device, may be employed to determine the signal levels transmitted by the control unit to the cell and for deriving the concentration level of the target analyte.
- In some embodiments, the subject invention includes a system characterized by one or more devices, each in the form of a micro-piercing member, a control unit, a display unit and a housing. Also provided by the subject inventions are kits for use in practicing the methods of the subject invention.
- The subject devices, systems, methods and kits find use in analyte concentration measurement of a variety of analytes and are particularly suited for use in the measurement of glucose concentration in interstitial fluid.
- FIG. 1 includes FIGS. 1A, 1B,1C and 1D wherein FIG. 1A is a partial cut-away view of a length of a micro-needle of the present invention, FIG. 1B is a cross-sectional view of the micro-needle of FIG. 1A along the arrows b-b, FIG. 1C is a cross-sectional view of the micro-needle of FIG. 1A along the arrows c-c and FIG. 1D is a top view of the micro-needle of FIG. 1A along the arrows d-d; and
- FIG. 2 is a schematic representation of the sampling and measurement device of the present invention.
- Percutaneous devices and systems, as well as methods for using the same are provided by the subject invention. A feature of the subject devices is the presence of a piercing member that includes concentric working and reference electrodes that define an electrochemical cell having a reaction area or zone into which accessed fluid flows and with which an electrochemical measurement of an analyte present in accessed fluid present therein is made. The present invention finds use in the sampling of biological fluids such as blood, blood fractions, interstitial fluid and the like, and in the detection and measurement of a variety of different analytes, e.g., glucose, cholesterol, electrolytes, pharmaceuticals, illicit drugs, and the like. In further describing the subject invention, a general overview is first provided. The subject devices, systems and methods for their use are discussed in greater detail, followed by a review of the subject kits.
- Before the present invention is described, it is to be understood that this invention is not limited to the particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a test strip” includes a plurality of such test strips and reference to “the processor” includes reference to one or more processors and equivalents thereof known to those skilled in the art, and so forth.
- The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
- The devices of the subject invention generally include a skin-penetration means, a fluid sampling means and a constituent measurement means, in many embodiments integrated into a single structure. The skin-penetration means has at least one micro-piercing member, e.g., a micro-needle or the like, used to penetrate the skin to a depth where pain and bleeding are minimized, and preferably non-existent. Thus, in many embodiments, the micro-needle penetrates above the level where nerves are present. As such, target skin layers into which the subject piercing members may extend to include the dermis, epidermis and the stratum corneum (i.e. the outermost layer of the epidermis).
- The devices further include a fluid sampling means, where such fluid sampling means is provided by the construct and geometry of the micro-needle itself, and more particularly, its internal construct and geometry. Specifically, the micro-needle has a generally elongated shape and an open distal tip extending into a space or spaces within its structure that are small enough to create a capillary force on fluid present at the open distal tip. The capillary force acts to access or draw the fluid (e.g., interstitial fluid and/or blood if so desired and depending on the length of the micro-needle) into a space within the micro-needle and then positions the sampled fluid to be measured by a measurement means.
- As mentioned above, a feature of the subject devices is a constituent measurement means. The constituent measurement means of the subject invention is made up of an electrochemical cell formed within the structure of the microneedle to measure the concentration of a constituent, e.g., an analyte, within the fluid sample. The electrochemical cell includes an electrode arrangement of a working electrode and a reference electrode that provides an input reference signal to the sampled fluid and an output signal representing the concentration of the target constituent or analyte in the sampled fluid. Various electrochemical systems may be employed by the present invention, including systems that are amperometric (i.e., measures current), coulometric (i.e., measures electrical charge) or potentiometric (i.e., measures voltage). These types of electrochemical measurement systems are well known to those of skill in the art. See e.g., U.S. Pat. Nos.: 4,224,125; 4,545,382; and 5,266,179; as well as WO 97/18465 and WO 99/49307, the disclosures of which are herein incorporated by reference.
- In many embodiments, the biological fluid sampling and analyte concentration measurements devices, e.g., micro-needles, of the invention each comprise at least two electrodes, a reference electrode and a working electrode. The reference electrode provides the input signal to the electrochemical cell and the working electrode provides the output measurement signal from the cell. In certain embodiments, the electrodes are separated by a porous insulator that defines a reaction zone within the micro-needle, where such a porous insulator acts to optimally position the electrodes with respect to each other. Additionally, the porous insulator acts as a component of the sampling means by providing a capillary-type wicking action or the like sufficient to move or draw sampled fluid into the electrochemical cell.
- In certain embodiments, the subject micro-needle includes a redox reagent system, typically on the reactive surface of one or both electrodes. Alternatively, the redox reagent system may be contained within the porous insulator. In either case, the redox reagent system typically comprises one or more enzymes and a mediator.
- In the subject invention, the electrochemical cell is in electrical communication with a control means that sets the input reference signal transmitted to the electrochemical cell, receives an output signal from the electrochemical cell and then derives the concentration level of the constituent within the sample from the output signal. In other words, the working and references electrodes are in electrical communication with a means for making an electrochemical measurement using the working and reference electrodes, e.g., a means for applying an electrical current between the two electrodes, measuring a change in the current over time and relating the observed change in current to the concentration of analyte present in the electrochemical cell. The detection and/or concentration of a constituent or analyte in a patient's or user's biological fluid, e.g., blood, is then derived from the concentration level in the fluid sample, the numerical value of which may then be displayed to the patient or user on a display unit.
- In many embodiments, the control and display units are integrally housed within a low-profile housing. The housing may take a form that also provides a means of securing or holding one or more micro-needles in a position and arrangement suitable for the particular sampling and measuring application at hand.
- As is apparent from the above discussion, the geometry and construct of the subject device provides three functions in a single micro-needle structure: penetration into the skin, collection of a sample of biological fluid and measurement of a constituent or analyte in that sample. In many embodiments, the collection and measurement steps are performed completely in-situ, obviating the conventional techniques of withdrawing a sample from the skin, placing the sample on a reagent test strip, or the like, and using a separate piece of equipment or means to test the sample. Thus, in-situ detection minimizes the lag time associated with obtaining measurement readings of a sample compared to previous diagnostic methods that rely on first extracting biological fluid before the measurement can take place.
- As summarized above, a feature of the subject invention is a skin-penetration means having at least one micro-piercing member, e.g., a micro-needle or the like. Furthermore, an aspect of the present invention is that it eliminates or at least greatly minimizes the pain and bleeding suffered by a patient during the sampling process. Accordingly, the penetration lengths and diameters of the micro-needles must be within certain ranges to accomplish this goal. Of course, those values will vary depending on the type of biological fluid (e.g., interstitial fluid, blood or both) desired for sampling, the skin layer to be accessed and the thickness of the skin layers of the particular patient or device user being tested.
- By way of background, the skin includes three distinct layers, a top layer called the epidermis, a middle layer called the dermis and a bottom layer called the subcutaneous layer. The epidermis is about 60 to 120 μm (microns) thick and comprises four distinct layers: a 10 to 20 μm outer layer, called the stratum corneum, followed by the stratum granulosum, stratum malpighii and stratum germinativum. The stratum corneum contains cells filled with bundles of cross-linked keratin and keratohyalin surrounded by an extracellular matrix of lipids. The inner three layers are collectively referred to as the viable epidermis and have a total thickness in the range of about 50 to 100 μm. The viable epidermis is responsible for diffusing metabolites to and from the dermis. The epidermis contains no blood cells or nerve endings. The dermis is much thicker than the epidermis, having a thickness in the range from about 2,000 to 3,000 μm. The dermal layer generally consists of a dense bed of connective tissue, including collagen fibers, and interstitial fluid dispersed throughout these fibers. Below the dermal layer is the subcutaneous tissue that contains the blood capillaries and the majority of nerve endings within the skin.
- Thus, in many embodiments, the micro-needles of the present invention may have lengths that extend no deeper than stratum comeum, the epidermis or the dermis layer when fully penetrated into the skin to minimize the pain felt by the patient; however, they may be longer if necessary for the particular sampling application at hand. Also, the length-to-diameter aspect ratio of the micro-needle is important in determining an optimal length for the subject micro-needles. Accordingly, in order to effectively and atraumatically penetrate the skin, the length of the micro-needle is usually at least about 5 times greater than the diameter of the micro-needle, but may be more or less. As will be further described below, the minimum micro-needle diameter is dependent upon the necessary spacing between the electrodes and the diameters of the other components of the electrochemical cell. Thus, the subject micro-needles generally have a length in the range from about 500 to 4,000 μm, typically between about 600 to 3,000 μm, and more typically between about 1,000 to 2,000 μm; however, these lengths will vary from patient to patient depending on the various factors as noted above, and on the thickness of the skin layers of the particular patient being tested. It will be apparent to one of skill in the art that while the micro-needles of the subject invention may have lengths that are longer than the depth of the target skin layer, the micro-needle may be penetrated into the skin at a depth (referred to as the penetration length) that is less than the length of the micro-needle structure. Thus, in order to minimize pain to the patient, the micro-needles in many embodiments have a penetration length in the range from about 50 to 4,000 μm, and more typically from about 100 to 3,000 μm. For example, for sampling applications which require penetration only into the epidermis layer, the penetration length of the micro-needle is typically between about 50 to 120 μm. For sampling applications which require penetration into but no deeper than the dermis layer, the penetration length of the micro-needle is typically from about 2,000 to 3,000 μm.
- The general configuration of an exemplary micro-needle of the present invention will now be described with reference to FIGS.1A-
D. Micro-needle 100 has a configuration that is substantially straight along the longitudinal axis and has a substantially circular cross-section. However, any suitable cross-sectional configuration may be employed including, but not limited to, other annular shapes such as elliptical and oblong, or polygonal configurations, such as square and rectangular. The outer diameter of a micro-needle at its thickest point typically does not exceed about 350 μm and is usually between about 200 μm to 300 μm. In certain embodiments the outer diameter is typically about 250 μm. -
Micro-needle 100 terminates atdistal end 104, in preferably asharp tip 102 having a beveled or sliced configuration, as shown in FIG. 1D, to more easily penetrate the skin. However,tip 102 may have other suitable configurations such as one that is not tapered and defines an edge that lies in a plane perpendicular to the longitudinal axis of the micro-needle (not shown). - Any suitable number of micro-needles, in the form of an array, may be employed by the present invention. The number of micro-needles employed will depend upon various factors including the agent being detected, the body surface location into which the micro-needles are inserted, the sample site, the fluid volume and the like. The micro-needle array may include micro-needles having varying shapes, lengths, widths and tip configurations.
- As discussed above, a feature of the subject invention is the presence, in the piercing means, of an electrochemical cell that is defined by concentric working and reference electrodes.
Micro-needle 100 includes an electrochemical cell that provides an electrical signal or signals representative of the concentration of the analyte being measured in a sampled biological fluid. The electrochemical cell comprises various components or layers arranged concentrically with respect to each other. In many embodiments, this concentric arrangement may also be circumferential or co-axial. - Viewed longitudinally in FIG. 1A and in cross-section in FIG. 1B, micro-needle100 includes, a
solid wire core 106 and anouter plating 114. Thesolid wire core 106 provides rigidity to the micro-needle structure and may be part of the adjacent electrode. Theouter plating 114 may be made of stainless steel or the like. Betweenwire core 106 andouter plating 114 resides the subject electrochemical cell, which includes, from inside out, a first orinner electrode 108, aporous insulator 110 and a second orouter electrode 112. - As shown in the proximal to distal end view of FIG. 1C taken along arrows c-c of FIG. 1A, second or
outer electrode 112 andouter plating 114 extend to defineedge 116 and tip 102 ofmicro-needle 100. The three innermost layers,insulator 110,first electrode 108 andsolid wire core 106, extend evenly to a location or area 118 (proximal to distal end 104), wherein these three layers have distal edges that are substantially flush with each other. These flush edges define the closedproximal end 122 of alumen portion 120 having a lumenal wall, defined bysecond electrode 112 andouter plating 114, which extends to a distal opening atdistal edge 116, as viewed in FIG. 1A.Lumen 120 acts to create a capillary force which wicks biological fluid present into lumen opening 128 attip 102.Lumen 120 has a volume which does not exceed about 250 nL and is generally in the range from about 20 to 140 nL. In certain embodiments the volume is typically about 65 nL.Porous insulator 110 then provides a secondary capillary force to wick an amount of the biological fluid contained withinlumen 120 into itself. -
Solid wire core 106 has a diameter which typically does not exceed about 120 μm, and more typically is in the general range from about 80 to 100 μm. In certain embodiments the diameter is typically about 90 μm.First electrode 108 has a cylindrical configuration (although other configurations are possible) having a thickness which typically does not exceed about 300 Δ, and more typically is in the general range from about 70 to 200 Δ. In certain embodiments the thickness is typically about 100 Δ.Porous insulator 110 also has a cylindrical configuration (although other configurations are possible) having a thickness which typically does not exceed about 200 μm, and more typically is in the general range from about 50 to 80 μm.Second electrode 112 also has a cylindrical configuration (although other configurations are possible) having a thickness which typically does not exceed about 300 Δ and more typically is in the general range from about 70 to 200 Δ. The thinouter tube 114 upon which thesecond electrode 112 is electroplated has a thickness which typically does not exceed about 25 μm and more typically is in the general range from about 12 to 20 μm. - The
electrode 112, i.e., the outer electrode, is used as the reference electrode, i.e., the electrode which provides an input signal to the electrochemical cell, and theother electrode 108, i.e., the inner electrode, is employed as a working electrode, i.e., the electrode which provides an output signal representative of the analyte concentration within the sampled fluid. Typically, the length of the outer electrode is the same as the length of the micro-needle, and thus is generally not greater than about 4,000 μm. More typically, the length of the outer electrode is between about 1,000 μm to 3,000 μm, and usually is about 2,000 μm. The inner electrode may have the same length as the outer electrode, but may often times be shorter than the outer electrode. The length of the inner electrode is generally about 20% shorter than the outer electrode and is generally not greater than about 3,200 μm, and is typically between about 800 to 2,400 μm, and is more typically about 1,600 μm. - At least the surfaces of the electrodes that face the reaction zone (i.e., the porous insulator) within the micro-needle are made of highly conductive metal, such as palladium, gold, platinum, silver, iridium, carbon, doped indium tin oxide, stainless steel and the like, or a combination of such materials. Most typically the metal is gold, platinum or palladium. Although the entire electrode may be made of metal, each electrode may be made up of an inert support or backing substrate, on the surface of which is a thin layer of the metal component (e.g., an electroplated metal layer) of the electrode.
- As mentioned above, the working and reference electrodes define the boundaries of the reaction zone that, in the embodiment of FIG. 1, is in the form of a cylindrical donut, for example. The reaction zone is filled with a hydrophilic porous insulator having an inner and an outer surface area and having a thickness that typically does not exceed 150 μm and generally is in the range from about 50 to 80 μm. The volume of the reaction zone typically does not exceed about 150 nL and is generally from about 15 to 110 nL. In certain embodiments the volume is typically about 50 nL.
- The porous insulator comprises pores or voids throughout at least a portion of the micro-needle structure. The pores are sufficiently sized to provide a capillary force so as to wick in fluid from
lumen 120. The pores are also sufficiently interconnected to permit passage of or conduction of a fluid through the porous material. The average pore size is from about 1000 to 5000 nm and more typically about 1000 to 2000 nm. The porous insulator may be made of ceramics or plastic materials such as polymers. Suitable types of polymer materials include, but are not limited to, polyimides, polysulfone, and cellulosic. As is well known in the art, polymers may be rendered porous by removing leachable or volatizable material contained therein. - A redox reagent(s) system is typically employed to single out and sense the target analyte or constituent selected to be analyzed over the other constituents in the sampled biological fluid. The redox reagent(s) of the redox reagent system may reside on the reactive surface, i.e., the surface facing the porous insulator, of one or both electrodes, but in many embodiments the redox reagent(s) will reside on the reactive surface of the working electrode. As such, the reagent is often times coated or deposited on the surface(s) by means of dip coating, where such processes are well known in the art. Alternatively, the reagent may be contained within the porous insulator by saturation coating, as is known in the art. The reagent system used is selected based on the analyte targeted for detection. The interaction of the reagent system and the corresponding constituent or analyte determines the concentration of the target analyte or constituent in the cell.
- The reagent system present in the reaction area typically includes at least an enzyme(s) and a mediator. In many embodiments, the enzyme member(s) of the reagent system is an enzyme or a plurality of enzymes that work in concert to oxidize the analyte of interest. In other words, the enzyme component of the reagent system is made up of a single analyte oxidizing enzyme or a collection of two or more enzymes that work in concert to oxidize the analyte of interest. Enzymes of interest include oxidases, dehydrogenases, lipases, kinases, diaphorases, quinoproteins and the like. The specific enzyme present in the reaction area depends on the particular analyte for which the electrochemical test strip is designed to detect, where representative enzymes include: glucose oxidase, glucose dehydrogenase, cholesterol esterase, cholesterol oxidase, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate oxidase, lactate oxidase, lactate dehydrogenase, pyruvate oxidase, alcohol oxidase, bilirubin oxidase, uricase, and the like. In many preferred embodiments where the analyte of interest is glucose, the enzyme component of the reagent system is a glucose-oxidizing enzyme (e.g., a glucose oxidase or glucose dehydrogenase).
- As described above, the reagent system may further include a second component, i.e., a mediator component, which is made up of one or more mediator agents. A variety of different mediator agents are known in the art and include: ferricyanide, phenazine ethosulphate, phenazine methosulfate, pheylenediamine, 1-methoxy-phenazine methosulfate, 2,6-dimethyl-1,4-benzoquinone, 2,5-dichloro-1,4-benzoquinone, ferrocene derivatives, osmium bipyridyl complexes, ruthenium complexes and the like. In those embodiments where glucose in the analyte of interest and glucose oxidase or glucose dehydrogenase is the enzyme components, mediator of particular interest is ferricyanide. Other reagents that may be present in the reaction area include buffering agents, (e.g., citraconate, citrate, phosphate), “Good” buffers and the like.
- The reagent(s) is generally present in dry form. The amounts of the various components may vary, wherein the amount of enzyme component typically ranges from about 0.1 to 10% by weight.
- As described above, the subject invention includes a system for sampling biological fluid from the skin of a patient or user and measuring a target constituent within the biological fluid, where such a system generally is made of at least one micro-needle having a sampling means, a reagent and an electrochemical cell, as described above, and a control unit having means for sending and receiving electrical signals and a software algorithm.
- Referring now to FIG. 2, there is shown a schematic representation of an
exemplary system 50 of the subject invention.System 50 includes a hand-heldcontrol unit 52 and adevice 10, as described above, operatively mounted todistal end 54 ofcontrol unit 52.Device 10 includes an array of the micro-needles of the present invention, such asmicro-needle 100 of FIG. 1.Control unit 52 has ahousing 56, typically made of a medical grade plastic material, having a low-profile configuration which houses a means (not shown) for controlling the measurement means ofdevice 10, i.e., generating and transmitting input reference signals to the electrochemical cell of micro-needle 100 and receiving output measurement signals from the cell.Housing 56 may further include a means for supporting the micro-needle array or a single micro-needle, such as a support or substrate or the like (not shown). - A software algorithm programmed within
control unit 52 automatically calculates and determines the concentration of the target analyte in the biological sample upon receipt of the output signal. The concentration level (among other desired information) is then transmitted to an external display means orscreen 58 that displays information to the user.Control interface buttons 60 are provided to allow the user to input information to the control means, such as the type of analyte targeted for measurement. -
Device 10 is electrically and physically coupled to controlunit 52. Electrical communication between the two is established by means of conductive contacts (not shown) ondevice 10 and corresponding electrical traces (not shown) withincontrol unit 52. In certain embodiments,device 10 andcontrol unit 52 are physically coupled by a quick lock-and-release mechanism (many of which are commonly known) such that a used device can be easily removed and replaced.Control unit 52 is typically reusable and usable with any number of devices of the subject invention. These features facilitate the taking of multiple samples and measurements in an efficient and rapid manner. - Also provided by the subject invention are methods for using the subject devices and systems to determine the concentration of an analyte in a biological sample. A variety of different analytes may be detected using the subject devices and systems, where representative analytes include, but are not limited to, glucose, cholesterol, lactate, alcohol, electrolytes, pharmaceuticals, illicit drugs, and the like.
- In practicing the subject methods (with reference to the Figures), the first step is to provide a
device 10 having one ormore micro-needles 100 of the present invention. In many embodiments,device 10 is particularly configured (i.e.,device 10 includes the appropriate reagent(s)) for targeting the analyte(s) of interest. Thedevice 10 is operatively engaged and interfaced with acontrol unit 52 that can be manually held and controlled by the user.Control unit 52 is programmed for testing the targeted analyte(s). Thedevice 10 is positioned over a selected area of the user's skin, and, with slight pressure, the array ofmicro-needles 100 ofdevice 10 are caused to penetrate into the skin. The depth to which the micro-needles 12 are inserted will depend on the length of the respective micro-needles or by some other means associated with thedevice 10 for limiting the insertion depth. - Upon insertion into the user's skin, an amount (i.e., a sample) of biological fluid present at the
open tips 102 ofmicro-needles 100 is caused to wick intolumens 120 of the respective micro-needles by means of a capillary force, i.e., most or all of the biological fluid is transferred in situ into thedevice 10. Theporous insulator 110 continues to wick the fluid into the reaction zone of the electrochemical cell by means of a capillary force. - As discussed above, micro-needle100 may be manufactured with a selected redox reagent system placed on opposing
surfaces first electrode 108 andsecond electrode 112, respectively, or alternatively, the reagent is infused withinporous insulator 110. The type of reagent system is selected based on the type of analyte targeted for measurement. Thus, when the sample of biological fluid is absorbed into theporous insulator 110, the targeted analyte within the sample chemically reacts with the reagent, causing the analyte to oxidize. This chemical reaction creates a change in the impedance (or resistance) level across the reaction zone within the electrochemical cell. - More specifically, once in the reaction zone, the targeted analyte chemically reacts with the selected reagent(s) to form electroactive products. The electroactive products are then either oxidized or reduced by the optional mediator or directly by the working
electrode 108. The resulting output signal level is then conducted to the control unit byelectrode 108. A software algorithm programmed withincontrol unit 52 then automatically determines the differential between the output and reference signals, derives the concentration of analyte in the sample from this differential value, and then derives the corresponding concentration level of the selected analyte in the patient's blood. Any or all of these values may be displayed by display means orscreen 58. - A device such as
control unit 52 which automatically calculates and determines the concentration of a selected analyte in a biological sample and/or in the patient's system, such that a user need only insert a micro-needle of the subject invention into the patient's skin and then read the final analyte concentration result from a display of the device, is further described in U.S. Pat. No. 6,193,873 entitled “Sample Detection to Initiate Timing of an Electrochemical Assay,” the disclosure of which is herein incorporated by reference. - Also provided by the subject invention are kits for use in practicing the subject methods. The kits of the subject invention include at least one subject device having one or more micro-needles. The kits may also include a reusable or disposable control unit that may be used with reusable or disposable devices of the kit or from other kits of the subject invention. These kits may include devices having an array of micro-needles having the same or different lengths. Certain kits may include various devices each containing the same or different reagents. Also, more than one reagent may be provided within a single micro-needle array, wherein one or more of the micro-needles are provided with a first reagent for testing a first target analyte and one or more other micro-needles are provided with other reagents for testing other targeted analytes. Finally, in many embodiments, the kits include instructions for using the subject devices in the determination of an analyte concentration in a physiological sample. These instructions may be present on one or more of the packaging, a label insert, or containers present in the kits, and the like.
- It is evident from the above description that the subject inventions are easy to use and can provide for analyte testing without the need to cut or lance the skin and with minimal or no pain and blood. As such, the subject invention represents a significant contribution to the field.
- The subject invention is shown and described herein in what is considered to be the most practical, and preferred embodiments. It is recognized, however, that departures may be made there from, which are within the scope of the invention, and that obvious modifications will occur to one skilled in the art upon reading this disclosure.
- Although the present invention is useful for many applications, the sampling of various biological fluids and the detection of many types of constituents, the invention has been described primarily in the context of the detection of analytes in interstitial fluids, and as being particularly useful for the detection of glucose in interstitial fluid. Thus, the specific devices and methods disclosed and the applications, biological fluids and constituents discussed herein are considered to be illustrative and not restrictive. Modifications that come within the meaning and range of equivalents of the disclosed concepts, such as those that would readily occur to one skilled in the art, are intended to be included within the scope of the appended claims.
Claims (33)
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/879,106 US6501976B1 (en) | 2001-06-12 | 2001-06-12 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
AU44451/02A AU784464B2 (en) | 2001-06-12 | 2002-05-29 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
ARP020102119A AR034379A1 (en) | 2001-06-12 | 2002-06-06 | PERCUTANEOUS SAMPLING DEVICE FOR BIOLOGICAL FLUIDS AND ANALYTIC MEASUREMENT |
MXPA02005619A MXPA02005619A (en) | 2001-06-12 | 2002-06-06 | Percutaneous biological fluid sampling and analyte measurement devices and methods. |
IL15009702A IL150097A (en) | 2001-06-12 | 2002-06-06 | Percutaneous bioligical fluid sampling and analyte measurement devices and methods |
CZ20022024A CZ20022024A3 (en) | 2001-06-12 | 2002-06-10 | Instrument and method for percutaneous taking a biological liquid and analyte measuring |
TW91112466A TWI234451B (en) | 2001-06-12 | 2002-06-10 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
RU2002115713/14A RU2002115713A (en) | 2001-06-12 | 2002-06-11 | Devices and methods for subcutaneous sampling of biological fluid and measurement of the analyte |
PL02354419A PL354419A1 (en) | 2001-06-12 | 2002-06-11 | Biological fluid sampling microneedle as well as method of and apparatus and system for transcutaneous biological fluid sampling and making corresponding analytical measurements |
CNB021243662A CN1273833C (en) | 2001-06-12 | 2002-06-11 | Device and method for sampling and testing components of biologic fluid via skin |
KR1020020032615A KR20020094899A (en) | 2001-06-12 | 2002-06-11 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
CA002390332A CA2390332A1 (en) | 2001-06-12 | 2002-06-11 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
EP02254055A EP1266625A3 (en) | 2001-06-12 | 2002-06-11 | Percutaneous biological fluid sampling and analyte measurement device |
JP2002170474A JP2003038464A (en) | 2001-06-12 | 2002-06-11 | Device and method for sampling percutaneous biological fluid and measuring analyte |
US10/284,582 US20030055326A1 (en) | 2001-06-12 | 2002-10-30 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
HK03101755.0A HK1049593A1 (en) | 2001-06-12 | 2003-03-11 | Percutaneous biological fluid sampling and analyte measurement device |
AU2006202678A AU2006202678A1 (en) | 2001-06-12 | 2006-06-23 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/879,106 US6501976B1 (en) | 2001-06-12 | 2001-06-12 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/284,582 Continuation US20030055326A1 (en) | 2001-06-12 | 2002-10-30 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020188185A1 true US20020188185A1 (en) | 2002-12-12 |
US6501976B1 US6501976B1 (en) | 2002-12-31 |
Family
ID=25373446
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/879,106 Expired - Lifetime US6501976B1 (en) | 2001-06-12 | 2001-06-12 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
US10/284,582 Abandoned US20030055326A1 (en) | 2001-06-12 | 2002-10-30 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/284,582 Abandoned US20030055326A1 (en) | 2001-06-12 | 2002-10-30 | Percutaneous biological fluid sampling and analyte measurement devices and methods |
Country Status (15)
Country | Link |
---|---|
US (2) | US6501976B1 (en) |
EP (1) | EP1266625A3 (en) |
JP (1) | JP2003038464A (en) |
KR (1) | KR20020094899A (en) |
CN (1) | CN1273833C (en) |
AR (1) | AR034379A1 (en) |
AU (1) | AU784464B2 (en) |
CA (1) | CA2390332A1 (en) |
CZ (1) | CZ20022024A3 (en) |
HK (1) | HK1049593A1 (en) |
IL (1) | IL150097A (en) |
MX (1) | MXPA02005619A (en) |
PL (1) | PL354419A1 (en) |
RU (1) | RU2002115713A (en) |
TW (1) | TWI234451B (en) |
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020188221A1 (en) * | 2001-06-12 | 2002-12-12 | Borzu Sohrab | Percutaneous biological fluid constituent sampling and measurement devices and methods |
US20040217018A1 (en) * | 2001-06-12 | 2004-11-04 | Koon-Wah Leong | Biological fluid sampling and analyte measurement devices and methods |
US20060264716A1 (en) * | 2005-04-25 | 2006-11-23 | Dennis Zander | Microneedle with glucose sensor and methods thereof |
EP1795127A2 (en) * | 2005-12-09 | 2007-06-13 | Fujifilm Corporation | Blood collection needle |
US20080058726A1 (en) * | 2006-08-30 | 2008-03-06 | Arvind Jina | Methods and Apparatus Incorporating a Surface Penetration Device |
WO2009064079A1 (en) * | 2007-11-12 | 2009-05-22 | Boditechmed Inc. | Percutaneous biological fluid sampling and pre shaking devices and methods |
US7654956B2 (en) | 2004-07-13 | 2010-02-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7771352B2 (en) | 1997-03-04 | 2010-08-10 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7792562B2 (en) | 1997-03-04 | 2010-09-07 | Dexcom, Inc. | Device and method for determining analyte levels |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US7860544B2 (en) | 1998-04-30 | 2010-12-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7881763B2 (en) | 2003-04-04 | 2011-02-01 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7927274B2 (en) | 2003-11-19 | 2011-04-19 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US7949382B2 (en) | 2005-03-29 | 2011-05-24 | Arkal Medical, Inc. | Devices, systems, methods and tools for continuous glucose monitoring |
US7976492B2 (en) | 2004-02-26 | 2011-07-12 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8000901B2 (en) | 2003-08-01 | 2011-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US8064977B2 (en) | 2002-05-22 | 2011-11-22 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8118877B2 (en) | 2003-05-21 | 2012-02-21 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
US8155723B2 (en) | 1997-03-04 | 2012-04-10 | Dexcom, Inc. | Device and method for determining analyte levels |
US8160671B2 (en) | 2003-12-05 | 2012-04-17 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
USRE43399E1 (en) | 2003-07-25 | 2012-05-22 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US8229535B2 (en) | 2008-02-21 | 2012-07-24 | Dexcom, Inc. | Systems and methods for blood glucose monitoring and alert delivery |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8280475B2 (en) | 2004-07-13 | 2012-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8287454B2 (en) | 1998-04-30 | 2012-10-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US8394021B2 (en) | 2003-08-01 | 2013-03-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8509871B2 (en) | 2001-07-27 | 2013-08-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8562558B2 (en) | 2007-06-08 | 2013-10-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8612159B2 (en) | 1998-04-30 | 2013-12-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8622905B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8652043B2 (en) | 2001-01-02 | 2014-02-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8777853B2 (en) | 2003-08-22 | 2014-07-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8840552B2 (en) | 2001-07-27 | 2014-09-23 | Dexcom, Inc. | Membrane for use with implantable devices |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9084570B2 (en) | 2010-10-08 | 2015-07-21 | Roche Diagnostics Operations, Inc. | Electrochemical sensor having symmetrically distributed analyte sensitive areas |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US9451910B2 (en) | 2007-09-13 | 2016-09-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US10653835B2 (en) | 2007-10-09 | 2020-05-19 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US10791928B2 (en) | 2007-05-18 | 2020-10-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US11589823B2 (en) | 2003-08-22 | 2023-02-28 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071384B2 (en) | 1997-12-22 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Control and calibration solutions and methods for their use |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US20050103624A1 (en) | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
US6603987B2 (en) * | 2000-07-11 | 2003-08-05 | Bayer Corporation | Hollow microneedle patch |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6855117B2 (en) | 2001-08-01 | 2005-02-15 | Johnson & Johnson Consumer Companies, Inc. | Method of treating the skin of a subject |
US6790179B2 (en) * | 2001-08-01 | 2004-09-14 | Johnson & Johnson Consumer Companies, Inc. | Method of examining and diagnosing skin health |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US6721586B2 (en) | 2001-06-12 | 2004-04-13 | Lifescan, Inc. | Percutaneous biological fluid sampling and analyte measurement devices and methods |
WO2002100460A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Electric lancet actuator |
US7316700B2 (en) | 2001-06-12 | 2008-01-08 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US6501976B1 (en) * | 2001-06-12 | 2002-12-31 | Lifescan, Inc. | Percutaneous biological fluid sampling and analyte measurement devices and methods |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US6749792B2 (en) * | 2001-07-09 | 2004-06-15 | Lifescan, Inc. | Micro-needles and methods of manufacture and use thereof |
US6952604B2 (en) * | 2001-12-21 | 2005-10-04 | Becton, Dickinson And Company | Minimally-invasive system and method for monitoring analyte levels |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
CA2444211C (en) * | 2002-10-11 | 2013-11-19 | Dermal Therapy (Barbados) Inc. | Determination of biological conditions using impedance measurements |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US7120483B2 (en) * | 2003-01-13 | 2006-10-10 | Isense Corporation | Methods for analyte sensing and measurement |
US20050177201A1 (en) * | 2003-03-31 | 2005-08-11 | Freeman Gary A. | Probe insertion pain reduction method and device |
ES2347248T3 (en) | 2003-05-30 | 2010-10-27 | Pelikan Technologies Inc. | PROCEDURE AND APPLIANCE FOR FLUID INJECTION. |
US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US20040253736A1 (en) * | 2003-06-06 | 2004-12-16 | Phil Stout | Analytical device with prediction module and related methods |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US7146202B2 (en) * | 2003-06-16 | 2006-12-05 | Isense Corporation | Compound material analyte sensor |
US8148164B2 (en) | 2003-06-20 | 2012-04-03 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
US8679853B2 (en) | 2003-06-20 | 2014-03-25 | Roche Diagnostics Operations, Inc. | Biosensor with laser-sealed capillary space and method of making |
PL1639354T3 (en) | 2003-06-20 | 2018-11-30 | F.Hoffmann-La Roche Ag | Test strip with slot vent opening |
US7452457B2 (en) | 2003-06-20 | 2008-11-18 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using dose sufficiency electrodes |
US8071030B2 (en) | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
US8058077B2 (en) | 2003-06-20 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Method for coding information on a biosensor test strip |
US7718439B2 (en) | 2003-06-20 | 2010-05-18 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
US7645373B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostic Operations, Inc. | System and method for coding information on a biosensor test strip |
US8206565B2 (en) | 2003-06-20 | 2012-06-26 | Roche Diagnostics Operation, Inc. | System and method for coding information on a biosensor test strip |
US7488601B2 (en) | 2003-06-20 | 2009-02-10 | Roche Diagnostic Operations, Inc. | System and method for determining an abused sensor during analyte measurement |
US7645421B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
EP1621132B1 (en) | 2003-06-27 | 2007-03-07 | Ehrfeld Mikrotechnik AG in Insolvenz | Device and method for sampling and analysing body fluids |
EP1522260A1 (en) * | 2003-06-27 | 2005-04-13 | Ehrfeld Mikrotechnik AG | Device for blood sampling and simultaneous quantitative determination of blood analytes |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
JP4312559B2 (en) * | 2003-09-19 | 2009-08-12 | 株式会社フジクラ | Sensor built-in needle, sample collection device, and sample inspection system |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US20050113739A1 (en) * | 2003-11-21 | 2005-05-26 | Matthias Stiene | Device and method for extracting body fluid |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
WO2005078118A1 (en) | 2004-02-06 | 2005-08-25 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
EP2335566A1 (en) * | 2004-06-16 | 2011-06-22 | iSense Corporation | Compound metal analyte sensor |
US7569126B2 (en) | 2004-06-18 | 2009-08-04 | Roche Diagnostics Operations, Inc. | System and method for quality assurance of a biosensor test strip |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
JP4631029B2 (en) * | 2005-06-27 | 2011-02-16 | 独立行政法人産業技術総合研究所 | Needle integrated biosensor |
WO2007013915A1 (en) | 2005-07-20 | 2007-02-01 | Bayer Healthcare Llc | Gated amperometry |
CN101273266B (en) | 2005-09-30 | 2012-08-22 | 拜尔健康护理有限责任公司 | Gated voltammetry |
US20070173706A1 (en) | 2005-11-11 | 2007-07-26 | Isense Corporation | Method and apparatus for insertion of a sensor |
WO2007091633A1 (en) * | 2006-02-09 | 2007-08-16 | The University Of Tokushima | Biodevice, contact part structure of biodevice, and biosensor |
KR100783966B1 (en) * | 2006-07-10 | 2007-12-10 | 현대자동차주식회사 | Body of ratation structure using springs and install structure for monitor of vehicle using it |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
KR100783965B1 (en) * | 2006-11-17 | 2007-12-10 | 현대자동차주식회사 | Roof type av display apparatus for vehicle |
TW200912298A (en) * | 2007-04-12 | 2009-03-16 | Arkray Inc | Analyzing tool |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
JP5581310B2 (en) * | 2008-03-17 | 2014-08-27 | アイセンス コーポレーション | Analyte sensor subassembly |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
US9033898B2 (en) * | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
EP2408369A1 (en) | 2009-03-02 | 2012-01-25 | Seventh Sense Biosystems, Inc. | Devices and methods for the analysis of an extractable medium |
US20110105872A1 (en) * | 2009-10-30 | 2011-05-05 | Seventh Sense Biosystems, Inc. | Systems and methods for application to skin and control of actuation, delivery, and/or perception thereof |
GR1007310B (en) | 2009-03-09 | 2011-06-10 | Αχιλλεας Τσουκαλης | Implantable biosensor with automatic calibration |
US10376213B2 (en) * | 2009-06-30 | 2019-08-13 | Waveform Technologies, Inc. | System, method and apparatus for sensor insertion |
US20110027458A1 (en) | 2009-07-02 | 2011-02-03 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
US9351677B2 (en) | 2009-07-02 | 2016-05-31 | Dexcom, Inc. | Analyte sensor with increased reference capacity |
WO2011053796A2 (en) * | 2009-10-30 | 2011-05-05 | Seventh Sense Biosystems, Inc. | Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin |
WO2011065972A2 (en) * | 2009-11-24 | 2011-06-03 | Seventh Sense Biosystems, Inc. | Patient-enacted sampling technique |
JP5806236B2 (en) * | 2010-01-13 | 2015-11-10 | セブンス センス バイオシステムズ,インコーポレーテッド | Rapid delivery and / or collection of fluids |
JP5826766B2 (en) * | 2010-01-13 | 2015-12-02 | セブンス センス バイオシステムズ,インコーポレーテッド | Sampling device interface |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9125625B2 (en) | 2010-06-10 | 2015-09-08 | The Regents Of The University Of California | Textile-based printable electrodes for electrochemical sensing |
DE102010030131B4 (en) * | 2010-06-15 | 2011-12-29 | Dow Deutschland Anlagengesellschaft Mbh | Hand-held device and method for testing a corrosion-prone metallic article for corrosion |
US20120016308A1 (en) | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure packaging for fluid devices |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
ES2565805T3 (en) | 2010-11-09 | 2016-04-07 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
EP2701598A1 (en) | 2011-04-29 | 2014-03-05 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
KR102013466B1 (en) | 2011-04-29 | 2019-08-22 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
JP2014516644A (en) | 2011-04-29 | 2014-07-17 | セブンス センス バイオシステムズ,インコーポレーテッド | Devices and methods for collection and / or manipulation of blood spots or other body fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
EP2750754B1 (en) | 2011-09-02 | 2021-03-24 | The Regents of the University of California | Microneedle arrays for biosensing and drug delivery |
CA2806765C (en) | 2012-03-08 | 2020-09-22 | Isense Corporation | Method and apparatus for insertion of a sensor |
US10820860B2 (en) | 2013-03-14 | 2020-11-03 | One Drop Biosensor Technologies, Llc | On-body microsensor for biomonitoring |
EP2972264A4 (en) | 2013-03-14 | 2016-12-07 | Sano Intelligence Inc | On-body microsensor for biomonitoring |
US10595754B2 (en) | 2014-03-13 | 2020-03-24 | Sano Intelligence, Inc. | System for monitoring body chemistry |
US20150257685A1 (en) | 2014-03-13 | 2015-09-17 | Sano Intelligence, Inc. | System for monitoring body chemistry |
US10814320B2 (en) * | 2016-08-08 | 2020-10-27 | Nalge Nunc International Corporation | Capillary transfer pipettes and related methods |
KR101822417B1 (en) | 2017-06-14 | 2018-01-29 | 주식회사 청도제약 | Means for determination of oxdative stress in human fluid |
CN112638253A (en) * | 2018-08-23 | 2021-04-09 | 雅培糖尿病护理股份有限公司 | Sensor and method for measuring pH |
CN109568124A (en) * | 2018-12-26 | 2019-04-05 | 汕头大学医学院第附属医院 | A kind of electrode catheter detection device and its application method |
EP4048152B1 (en) | 2020-07-29 | 2023-12-20 | Biolinq Incorporated | Continuous analyte monitoring system with microneedle array |
USD988882S1 (en) | 2021-04-21 | 2023-06-13 | Informed Data Systems Inc. | Sensor assembly |
US11857344B2 (en) | 2021-05-08 | 2024-01-02 | Biolinq Incorporated | Fault detection for microneedle array based continuous analyte monitoring device |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682162A (en) * | 1968-12-13 | 1972-08-08 | Wellcome Found | Combined electrode and hypodermic syringe needle |
US3957613A (en) * | 1974-11-01 | 1976-05-18 | General Electric Company | Miniature probe having multifunctional electrodes for sensing ions and gases |
US4805624A (en) * | 1985-09-09 | 1989-02-21 | The Montefiore Hospital Association Of Western Pa | Low-potential electrochemical redox sensors |
DK61488D0 (en) * | 1988-02-05 | 1988-02-05 | Novo Industri As | COURSE OF ACTION |
US5161532A (en) | 1990-04-19 | 1992-11-10 | Teknekron Sensor Development Corporation | Integral interstitial fluid sensor |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
AUPN363995A0 (en) | 1995-06-19 | 1995-07-13 | Memtec Limited | Electrochemical cell |
US5879367A (en) | 1995-09-08 | 1999-03-09 | Integ, Inc. | Enhanced interstitial fluid collection |
WO1997010745A1 (en) | 1995-09-08 | 1997-03-27 | Integ, Inc. | Body fluid sampler |
WO1997015827A1 (en) * | 1995-10-25 | 1997-05-01 | Wilkins Ebtisam S | Coated wire sensor |
AUPN661995A0 (en) | 1995-11-16 | 1995-12-07 | Memtec America Corporation | Electrochemical cell 2 |
AU3070397A (en) | 1996-05-17 | 1997-12-05 | Mercury Diagnostics Inc. | Methods and apparatus for sampling body fluid |
CA2259437C (en) | 1996-07-03 | 2006-12-05 | Altea Technologies, Inc. | Multiple mechanical microporation of skin or mucosa |
US5913833A (en) | 1997-02-07 | 1999-06-22 | Abbott Laboratories | Method and apparatus for obtaining biological fluids |
US6139718A (en) * | 1997-03-25 | 2000-10-31 | Cygnus, Inc. | Electrode with improved signal to noise ratio |
US6503198B1 (en) | 1997-09-11 | 2003-01-07 | Jack L. Aronowtiz | Noninvasive transdermal systems for detecting an analyte obtained from or underneath skin and methods |
US6155992A (en) | 1997-12-02 | 2000-12-05 | Abbott Laboratories | Method and apparatus for obtaining interstitial fluid for diagnostic tests |
PT1037686E (en) | 1997-12-11 | 2005-10-31 | Alza Corp | APPARATUS FOR POTENTIATING THE FLOW OF TRANSDERMMIC AGENT |
US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
WO1999064580A1 (en) | 1998-06-10 | 1999-12-16 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
JP3398598B2 (en) * | 1998-06-10 | 2003-04-21 | 松下電器産業株式会社 | Substrate quantification method and analytical element and measuring device used for the method |
JP3433789B2 (en) * | 1998-06-11 | 2003-08-04 | 松下電器産業株式会社 | Electrode probe and body fluid testing device provided with the same |
US6248067B1 (en) * | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
JP2002532165A (en) | 1998-12-18 | 2002-10-02 | メドトロニック ミニメド インコーポレイテッド | Insert set with micro-piercing member for use with a medical device and method of using such insert set |
AU768000B2 (en) | 1999-02-04 | 2003-11-27 | Integ, Inc. | Needle for body fluid tester |
US6360888B1 (en) * | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US7577469B1 (en) | 1999-03-11 | 2009-08-18 | Jack L. Aronowitz | Noninvasive transdermal systems for detecting an analyte in a biological fluid and methods |
EP1187653B1 (en) | 1999-06-04 | 2010-03-31 | Georgia Tech Research Corporation | Devices for enhanced microneedle penetration of biological barriers |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6379324B1 (en) * | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
JP3985022B2 (en) * | 1999-11-08 | 2007-10-03 | アークレイ株式会社 | Body fluid measuring device and insertion body used by being inserted into the body fluid measuring device |
US6501976B1 (en) * | 2001-06-12 | 2002-12-31 | Lifescan, Inc. | Percutaneous biological fluid sampling and analyte measurement devices and methods |
-
2001
- 2001-06-12 US US09/879,106 patent/US6501976B1/en not_active Expired - Lifetime
-
2002
- 2002-05-29 AU AU44451/02A patent/AU784464B2/en not_active Ceased
- 2002-06-06 AR ARP020102119A patent/AR034379A1/en unknown
- 2002-06-06 MX MXPA02005619A patent/MXPA02005619A/en active IP Right Grant
- 2002-06-06 IL IL15009702A patent/IL150097A/en not_active IP Right Cessation
- 2002-06-10 CZ CZ20022024A patent/CZ20022024A3/en unknown
- 2002-06-10 TW TW91112466A patent/TWI234451B/en not_active IP Right Cessation
- 2002-06-11 CN CNB021243662A patent/CN1273833C/en not_active Expired - Fee Related
- 2002-06-11 JP JP2002170474A patent/JP2003038464A/en active Pending
- 2002-06-11 KR KR1020020032615A patent/KR20020094899A/en not_active Application Discontinuation
- 2002-06-11 PL PL02354419A patent/PL354419A1/en unknown
- 2002-06-11 EP EP02254055A patent/EP1266625A3/en not_active Ceased
- 2002-06-11 RU RU2002115713/14A patent/RU2002115713A/en not_active Application Discontinuation
- 2002-06-11 CA CA002390332A patent/CA2390332A1/en not_active Abandoned
- 2002-10-30 US US10/284,582 patent/US20030055326A1/en not_active Abandoned
-
2003
- 2003-03-11 HK HK03101755.0A patent/HK1049593A1/en unknown
Cited By (346)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7835777B2 (en) | 1997-03-04 | 2010-11-16 | Dexcom, Inc. | Device and method for determining analyte levels |
US9931067B2 (en) | 1997-03-04 | 2018-04-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US9439589B2 (en) | 1997-03-04 | 2016-09-13 | Dexcom, Inc. | Device and method for determining analyte levels |
US9339223B2 (en) | 1997-03-04 | 2016-05-17 | Dexcom, Inc. | Device and method for determining analyte levels |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US8923947B2 (en) | 1997-03-04 | 2014-12-30 | Dexcom, Inc. | Device and method for determining analyte levels |
US8676288B2 (en) | 1997-03-04 | 2014-03-18 | Dexcom, Inc. | Device and method for determining analyte levels |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US8527025B1 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US8155723B2 (en) | 1997-03-04 | 2012-04-10 | Dexcom, Inc. | Device and method for determining analyte levels |
US7974672B2 (en) | 1997-03-04 | 2011-07-05 | Dexcom, Inc. | Device and method for determining analyte levels |
US7771352B2 (en) | 1997-03-04 | 2010-08-10 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7970448B2 (en) | 1997-03-04 | 2011-06-28 | Dexcom, Inc. | Device and method for determining analyte levels |
US7792562B2 (en) | 1997-03-04 | 2010-09-07 | Dexcom, Inc. | Device and method for determining analyte levels |
US7901354B2 (en) | 1997-03-04 | 2011-03-08 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US8666469B2 (en) | 1998-04-30 | 2014-03-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8353829B2 (en) | 1998-04-30 | 2013-01-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8734348B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7860544B2 (en) | 1998-04-30 | 2010-12-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7869853B1 (en) | 1998-04-30 | 2011-01-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8744545B2 (en) | 1998-04-30 | 2014-06-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8734346B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7885699B2 (en) | 1998-04-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8672844B2 (en) | 1998-04-30 | 2014-03-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8670815B2 (en) | 1998-04-30 | 2014-03-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8738109B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8774887B2 (en) | 1998-04-30 | 2014-07-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8660627B2 (en) | 1998-04-30 | 2014-02-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8649841B2 (en) | 1998-04-30 | 2014-02-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8641619B2 (en) | 1998-04-30 | 2014-02-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8622906B2 (en) | 1998-04-30 | 2014-01-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8617071B2 (en) | 1998-04-30 | 2013-12-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8612159B2 (en) | 1998-04-30 | 2013-12-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8597189B2 (en) | 1998-04-30 | 2013-12-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8840553B2 (en) | 1998-04-30 | 2014-09-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8880137B2 (en) | 1998-04-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9014773B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011331B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9042953B2 (en) | 1998-04-30 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8473021B2 (en) | 1998-04-30 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8162829B2 (en) | 1998-04-30 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8175673B2 (en) | 1998-04-30 | 2012-05-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8177716B2 (en) | 1998-04-30 | 2012-05-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8224413B2 (en) | 1998-04-30 | 2012-07-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226557B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066694B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226555B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066697B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226558B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9072477B2 (en) | 1998-04-30 | 2015-07-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8231532B2 (en) | 1998-04-30 | 2012-07-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8235896B2 (en) | 1998-04-30 | 2012-08-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8409131B2 (en) | 1998-04-30 | 2013-04-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8255031B2 (en) | 1998-04-30 | 2012-08-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8260392B2 (en) | 1998-04-30 | 2012-09-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8265726B2 (en) | 1998-04-30 | 2012-09-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8273022B2 (en) | 1998-04-30 | 2012-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8275439B2 (en) | 1998-04-30 | 2012-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8391945B2 (en) | 1998-04-30 | 2013-03-05 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8380273B2 (en) | 1998-04-30 | 2013-02-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8372005B2 (en) | 1998-04-30 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8366614B2 (en) | 1998-04-30 | 2013-02-05 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8357091B2 (en) | 1998-04-30 | 2013-01-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8287454B2 (en) | 1998-04-30 | 2012-10-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346336B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326714B2 (en) | 1998-04-30 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8306598B2 (en) | 1998-04-30 | 2012-11-06 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8652043B2 (en) | 2001-01-02 | 2014-02-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011332B2 (en) | 2001-01-02 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9610034B2 (en) | 2001-01-02 | 2017-04-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8668645B2 (en) | 2001-01-02 | 2014-03-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9498159B2 (en) | 2001-01-02 | 2016-11-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6793632B2 (en) * | 2001-06-12 | 2004-09-21 | Lifescan, Inc. | Percutaneous biological fluid constituent sampling and measurement devices and methods |
US20020188221A1 (en) * | 2001-06-12 | 2002-12-12 | Borzu Sohrab | Percutaneous biological fluid constituent sampling and measurement devices and methods |
US20040217018A1 (en) * | 2001-06-12 | 2004-11-04 | Koon-Wah Leong | Biological fluid sampling and analyte measurement devices and methods |
US9804114B2 (en) | 2001-07-27 | 2017-10-31 | Dexcom, Inc. | Sensor head for use with implantable devices |
US8840552B2 (en) | 2001-07-27 | 2014-09-23 | Dexcom, Inc. | Membrane for use with implantable devices |
US8509871B2 (en) | 2001-07-27 | 2013-08-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9328371B2 (en) | 2001-07-27 | 2016-05-03 | Dexcom, Inc. | Sensor head for use with implantable devices |
US10039480B2 (en) | 2001-07-27 | 2018-08-07 | Dexcom, Inc. | Membrane for use with implantable devices |
US9532741B2 (en) | 2001-07-27 | 2017-01-03 | Dexcom, Inc. | Membrane for use with implantable devices |
US9549693B2 (en) | 2002-05-22 | 2017-01-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8064977B2 (en) | 2002-05-22 | 2011-11-22 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US11020026B2 (en) | 2002-05-22 | 2021-06-01 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US10052051B2 (en) | 2002-05-22 | 2018-08-21 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8543184B2 (en) | 2002-05-22 | 2013-09-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US7881763B2 (en) | 2003-04-04 | 2011-02-01 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US8118877B2 (en) | 2003-05-21 | 2012-02-21 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7896809B2 (en) | 2003-07-25 | 2011-03-01 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10376143B2 (en) | 2003-07-25 | 2019-08-13 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
USRE43399E1 (en) | 2003-07-25 | 2012-05-22 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8986209B2 (en) | 2003-08-01 | 2015-03-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8788006B2 (en) | 2003-08-01 | 2014-07-22 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8622905B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8700117B2 (en) | 2003-08-01 | 2014-04-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8000901B2 (en) | 2003-08-01 | 2011-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8394021B2 (en) | 2003-08-01 | 2013-03-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8676287B2 (en) | 2003-08-01 | 2014-03-18 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8788007B2 (en) | 2003-08-01 | 2014-07-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9510782B2 (en) | 2003-08-22 | 2016-12-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US9585607B2 (en) | 2003-08-22 | 2017-03-07 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8777853B2 (en) | 2003-08-22 | 2014-07-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11589823B2 (en) | 2003-08-22 | 2023-02-28 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9420968B2 (en) | 2003-08-22 | 2016-08-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8282550B2 (en) | 2003-11-19 | 2012-10-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US7927274B2 (en) | 2003-11-19 | 2011-04-19 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US11564602B2 (en) | 2003-11-19 | 2023-01-31 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US8483793B2 (en) | 2003-12-05 | 2013-07-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
USRE44695E1 (en) | 2003-12-05 | 2014-01-07 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8249684B2 (en) | 2003-12-05 | 2012-08-21 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US8428678B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8160671B2 (en) | 2003-12-05 | 2012-04-17 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8911369B2 (en) | 2003-12-05 | 2014-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10188333B2 (en) | 2003-12-05 | 2019-01-29 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8929968B2 (en) | 2003-12-05 | 2015-01-06 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11020031B1 (en) | 2003-12-05 | 2021-06-01 | Dexcom, Inc. | Analyte sensor |
US9579053B2 (en) | 2003-12-05 | 2017-02-28 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10299712B2 (en) | 2003-12-05 | 2019-05-28 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8721585B2 (en) | 2004-02-26 | 2014-05-13 | Dex Com, Inc. | Integrated delivery device for continuous glucose sensor |
US11246990B2 (en) | 2004-02-26 | 2022-02-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8882741B2 (en) | 2004-02-26 | 2014-11-11 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US9937293B2 (en) | 2004-02-26 | 2018-04-10 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8920401B2 (en) | 2004-02-26 | 2014-12-30 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10278580B2 (en) | 2004-02-26 | 2019-05-07 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US7976492B2 (en) | 2004-02-26 | 2011-07-12 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US9155843B2 (en) | 2004-02-26 | 2015-10-13 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10835672B2 (en) | 2004-02-26 | 2020-11-17 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US9050413B2 (en) | 2004-02-26 | 2015-06-09 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US10966609B2 (en) | 2004-02-26 | 2021-04-06 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8926585B2 (en) | 2004-02-26 | 2015-01-06 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9833143B2 (en) | 2004-05-03 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10327638B2 (en) | 2004-05-03 | 2019-06-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US8825127B2 (en) | 2004-07-13 | 2014-09-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US8571625B2 (en) | 2004-07-13 | 2013-10-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8858434B2 (en) | 2004-07-13 | 2014-10-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565849B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8801611B2 (en) | 2004-07-13 | 2014-08-12 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US10314525B2 (en) | 2004-07-13 | 2019-06-11 | Dexcom, Inc. | Analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US8792953B2 (en) | 2004-07-13 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8792954B2 (en) | 2004-07-13 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8731630B2 (en) | 2004-07-13 | 2014-05-20 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8548551B2 (en) | 2004-07-13 | 2013-10-01 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8989833B2 (en) | 2004-07-13 | 2015-03-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US8515516B2 (en) | 2004-07-13 | 2013-08-20 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8515519B2 (en) | 2004-07-13 | 2013-08-20 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US9044199B2 (en) * | 2004-07-13 | 2015-06-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8615282B2 (en) | 2004-07-13 | 2013-12-24 | Dexcom, Inc. | Analyte sensor |
US8483791B2 (en) | 2004-07-13 | 2013-07-09 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9060742B2 (en) | 2004-07-13 | 2015-06-23 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8475373B2 (en) | 2004-07-13 | 2013-07-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8463350B2 (en) | 2004-07-13 | 2013-06-11 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8457708B2 (en) | 2004-07-13 | 2013-06-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9078626B2 (en) | 2004-07-13 | 2015-07-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10022078B2 (en) * | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US8663109B2 (en) | 2004-07-13 | 2014-03-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8721545B2 (en) | 2004-07-13 | 2014-05-13 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8750955B2 (en) | 2004-07-13 | 2014-06-10 | Dexcom, Inc. | Analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US7949381B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US8313434B2 (en) | 2004-07-13 | 2012-11-20 | Dexcom, Inc. | Analyte sensor inserter system |
US9055901B2 (en) | 2004-07-13 | 2015-06-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US8812072B2 (en) | 2004-07-13 | 2014-08-19 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8290560B2 (en) | 2004-07-13 | 2012-10-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8280475B2 (en) | 2004-07-13 | 2012-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US9833176B2 (en) | 2004-07-13 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9814414B2 (en) | 2004-07-13 | 2017-11-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US8231531B2 (en) | 2004-07-13 | 2012-07-31 | Dexcom, Inc. | Analyte sensor |
US9801572B2 (en) | 2004-07-13 | 2017-10-31 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8229534B2 (en) | 2004-07-13 | 2012-07-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7654956B2 (en) | 2004-07-13 | 2010-02-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US8690775B2 (en) | 2004-07-13 | 2014-04-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9603557B2 (en) | 2004-07-13 | 2017-03-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US9610031B2 (en) | 2004-07-13 | 2017-04-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US9668677B2 (en) | 2004-07-13 | 2017-06-06 | Dexcom, Inc. | Analyte sensor |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9775543B2 (en) | 2004-07-13 | 2017-10-03 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9918668B2 (en) | 2005-03-10 | 2018-03-20 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10624539B2 (en) | 2005-03-10 | 2020-04-21 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9314196B2 (en) | 2005-03-10 | 2016-04-19 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610102B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8579816B2 (en) | 2005-03-10 | 2013-11-12 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9220449B2 (en) | 2005-03-10 | 2015-12-29 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9078608B2 (en) | 2005-03-10 | 2015-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8611978B2 (en) | 2005-03-10 | 2013-12-17 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8560037B2 (en) | 2005-03-10 | 2013-10-15 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7949382B2 (en) | 2005-03-29 | 2011-05-24 | Arkal Medical, Inc. | Devices, systems, methods and tools for continuous glucose monitoring |
US8280476B2 (en) | 2005-03-29 | 2012-10-02 | Arkal Medical, Inc. | Devices, systems, methods and tools for continuous glucose monitoring |
US10376188B2 (en) | 2005-04-15 | 2019-08-13 | Dexcom, Inc. | Analyte sensing biointerface |
US9788766B2 (en) | 2005-04-15 | 2017-10-17 | Dexcom, Inc. | Analyte sensing biointerface |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US10702193B2 (en) | 2005-04-15 | 2020-07-07 | Dexcom, Inc. | Analyte sensing biointerface |
US10667730B2 (en) | 2005-04-15 | 2020-06-02 | Dexcom, Inc. | Analyte sensing biointerface |
US10667729B2 (en) | 2005-04-15 | 2020-06-02 | Dexcom, Inc. | Analyte sensing biointerface |
US20060264716A1 (en) * | 2005-04-25 | 2006-11-23 | Dennis Zander | Microneedle with glucose sensor and methods thereof |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10709332B2 (en) | 2005-06-21 | 2020-07-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10610103B2 (en) | 2005-06-21 | 2020-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8915850B2 (en) | 2005-11-01 | 2014-12-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326716B2 (en) | 2005-11-01 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11911151B1 (en) | 2005-11-01 | 2024-02-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10231654B2 (en) | 2005-11-01 | 2019-03-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8920319B2 (en) | 2005-11-01 | 2014-12-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10201301B2 (en) | 2005-11-01 | 2019-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11103165B2 (en) | 2005-11-01 | 2021-08-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10952652B2 (en) | 2005-11-01 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11272867B2 (en) | 2005-11-01 | 2022-03-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11363975B2 (en) | 2005-11-01 | 2022-06-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11399748B2 (en) | 2005-11-01 | 2022-08-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
EP1795127A3 (en) * | 2005-12-09 | 2008-02-27 | Fujifilm Corporation | Blood collection needle |
EP1795127A2 (en) * | 2005-12-09 | 2007-06-13 | Fujifilm Corporation | Blood collection needle |
US20070149944A1 (en) * | 2005-12-09 | 2007-06-28 | Fujifilm Corporation | Blood collecting needle |
US11191458B2 (en) | 2006-01-17 | 2021-12-07 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US11596332B2 (en) | 2006-01-17 | 2023-03-07 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US10265000B2 (en) | 2006-01-17 | 2019-04-23 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
US9724028B2 (en) | 2006-02-22 | 2017-08-08 | Dexcom, Inc. | Analyte sensor |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20080058726A1 (en) * | 2006-08-30 | 2008-03-06 | Arvind Jina | Methods and Apparatus Incorporating a Surface Penetration Device |
US9504413B2 (en) | 2006-10-04 | 2016-11-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10349873B2 (en) | 2006-10-04 | 2019-07-16 | Dexcom, Inc. | Analyte sensor |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10136844B2 (en) | 2006-10-04 | 2018-11-27 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US11399745B2 (en) | 2006-10-04 | 2022-08-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10791928B2 (en) | 2007-05-18 | 2020-10-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10403012B2 (en) | 2007-06-08 | 2019-09-03 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US11373347B2 (en) | 2007-06-08 | 2022-06-28 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8562558B2 (en) | 2007-06-08 | 2013-10-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9741139B2 (en) | 2007-06-08 | 2017-08-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9451910B2 (en) | 2007-09-13 | 2016-09-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11672422B2 (en) | 2007-09-13 | 2023-06-13 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9668682B2 (en) | 2007-09-13 | 2017-06-06 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10653835B2 (en) | 2007-10-09 | 2020-05-19 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US11744943B2 (en) | 2007-10-09 | 2023-09-05 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US11160926B1 (en) | 2007-10-09 | 2021-11-02 | Dexcom, Inc. | Pre-connected analyte sensors |
US9717449B2 (en) | 2007-10-25 | 2017-08-01 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11272869B2 (en) | 2007-10-25 | 2022-03-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10182751B2 (en) | 2007-10-25 | 2019-01-22 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
USRE46250E1 (en) | 2007-11-12 | 2016-12-27 | Boditechmed Inc. | Biological fluid sampling and pretreating system and a method thereof |
US8491499B2 (en) | 2007-11-12 | 2013-07-23 | Boditechmed Inc | Biological fluid sampling and pretreating system and a method thereof |
WO2009064079A1 (en) * | 2007-11-12 | 2009-05-22 | Boditechmed Inc. | Percutaneous biological fluid sampling and pre shaking devices and methods |
US20100286557A1 (en) * | 2007-11-12 | 2010-11-11 | Boditechmed Inc. | Percutaneous biological fluid sampling and pre shaking devices and methods |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149233B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10827980B2 (en) | 2007-12-17 | 2020-11-10 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10506982B2 (en) | 2007-12-17 | 2019-12-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9339238B2 (en) | 2007-12-17 | 2016-05-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11342058B2 (en) | 2007-12-17 | 2022-05-24 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9901307B2 (en) | 2007-12-17 | 2018-02-27 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149234B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9143569B2 (en) | 2008-02-21 | 2015-09-22 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8229535B2 (en) | 2008-02-21 | 2012-07-24 | Dexcom, Inc. | Systems and methods for blood glucose monitoring and alert delivery |
US9020572B2 (en) | 2008-02-21 | 2015-04-28 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8591455B2 (en) | 2008-02-21 | 2013-11-26 | Dexcom, Inc. | Systems and methods for customizing delivery of sensor data |
US11102306B2 (en) | 2008-02-21 | 2021-08-24 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US10602968B2 (en) | 2008-03-25 | 2020-03-31 | Dexcom, Inc. | Analyte sensor |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US11896374B2 (en) | 2008-03-25 | 2024-02-13 | Dexcom, Inc. | Analyte sensor |
US10028683B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10561352B2 (en) | 2008-09-19 | 2020-02-18 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US9339222B2 (en) | 2008-09-19 | 2016-05-17 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US11918354B2 (en) | 2008-09-19 | 2024-03-05 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10028684B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10349878B2 (en) | 2010-10-08 | 2019-07-16 | Roche Diabetes Care, Inc. | Electrochemical sensor having symmetrically distributed analyte sensitive areas |
US9084570B2 (en) | 2010-10-08 | 2015-07-21 | Roche Diagnostics Operations, Inc. | Electrochemical sensor having symmetrically distributed analyte sensitive areas |
US9757060B2 (en) | 2010-10-08 | 2017-09-12 | Roche Diabetes Care, Inc. | Electrochemical sensor having symmetrically distributed analyte sensitive areas |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
Also Published As
Publication number | Publication date |
---|---|
JP2003038464A (en) | 2003-02-12 |
MXPA02005619A (en) | 2004-09-10 |
CN1273833C (en) | 2006-09-06 |
EP1266625A3 (en) | 2003-08-20 |
CA2390332A1 (en) | 2002-12-12 |
EP1266625A2 (en) | 2002-12-18 |
RU2002115713A (en) | 2003-12-27 |
KR20020094899A (en) | 2002-12-18 |
US20030055326A1 (en) | 2003-03-20 |
HK1049593A1 (en) | 2003-05-23 |
US6501976B1 (en) | 2002-12-31 |
CN1391104A (en) | 2003-01-15 |
CZ20022024A3 (en) | 2003-12-17 |
TWI234451B (en) | 2005-06-21 |
IL150097A0 (en) | 2002-12-01 |
AR034379A1 (en) | 2004-02-18 |
PL354419A1 (en) | 2002-12-16 |
AU784464B2 (en) | 2006-04-06 |
AU4445102A (en) | 2002-12-19 |
IL150097A (en) | 2005-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6501976B1 (en) | Percutaneous biological fluid sampling and analyte measurement devices and methods | |
US6793632B2 (en) | Percutaneous biological fluid constituent sampling and measurement devices and methods | |
US6990367B2 (en) | Percutaneous biological fluid sampling and analyte measurement devices and methods | |
US6837988B2 (en) | Biological fluid sampling and analyte measurement devices and methods | |
US7361307B2 (en) | Biological fluid constituent sampling and measurement devices | |
US20030028087A1 (en) | Devices for analyte concentration determination and methods of using the same | |
AU2006202678A1 (en) | Percutaneous biological fluid sampling and analyte measurement devices and methods | |
AU2006202256A1 (en) | Percutaneous biological fluid constituent sampling and measurement devices and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIFESCAN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOHRAB, BORZU;REEL/FRAME:012162/0765 Effective date: 20010906 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH CAROLINA Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047179/0150 Effective date: 20181001 Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047179/0150 Effective date: 20181001 |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH CAROLINA Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047186/0836 Effective date: 20181001 Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047186/0836 Effective date: 20181001 |
|
AS | Assignment |
Owner name: LIFESCAN IP HOLDINGS, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CILAG GMBH INTERNATIONAL;REEL/FRAME:050837/0001 Effective date: 20181001 Owner name: CILAG GMBH INTERNATIONAL, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIFESCAN INC.;REEL/FRAME:050836/0737 Effective date: 20181001 |
|
AS | Assignment |
Owner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEY Free format text: RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:064206/0176 Effective date: 20230627 Owner name: JANSSEN BIOTECH, INC., PENNSYLVANIA Free format text: RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:064206/0176 Effective date: 20230627 Owner name: LIFESCAN IP HOLDINGS, LLC, CALIFORNIA Free format text: RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:064206/0176 Effective date: 20230627 |
|
AS | Assignment |
Owner name: CILAG GMBH INTERNATIONAL, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY LIST BY ADDING PATENTS 6990849;7169116; 7351770;7462265;7468125; 7572356;8093903; 8486245;8066866;AND DELETE 10881560. PREVIOUSLY RECORDED ON REEL 050836 FRAME 0737. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:LIFESCAN INC.;REEL/FRAME:064782/0443 Effective date: 20181001 |